Report date: Friday, July 31, 2026, before the market opens
Conference call: 8:30 a.m. ET (investor.colgatepalmolive.com)
July 30 closing price: $91.62
The central question is not whether Colgate-Palmolive can deliver another modest EPS beat. It is whether the company can protect its 2026 earnings outlook while commodity, freight and tariff pressures intensify.
Colgate entered the quarter with good emerging-market momentum, improving Asian performance and a healthy core Hill’s business. Those positives are offset by a weak North American franchise, slowing U.S. categories and significantly higher oil-linked input and logistics costs.
The most consequential parts of Friday’s report should be:
The setup appears balanced. Expectations are not especially demanding for Q2, but CL trades at a premium valuation and has already outperformed the broader market this year. A routine beat accompanied by cautious guidance may not be enough to drive substantial upside.
Public estimate aggregators are not fully aligned, but a commonly cited consensus calls for approximately:
| Metric | Q2 2026 consensus | Q2 2025 actual | Implied change |
|---|---|---|---|
| Revenue | $5.36 billion | $5.11 billion | +4.9% |
| Adjusted EPS | $0.95 | $0.92 | +3.3% |
Some estimate feeds show figures closer to $0.97 of EPS and $5.5 billion of revenue, so investors should treat the exact consensus as provider-dependent. (benzinga.com)
Reported revenue growth should receive meaningful help from currencies. Consequently, organic sales, volume, pricing and gross margin will carry more information than the headline revenue number.
First-quarter results were solid:
The geographic split was stark: North American organic sales fell 2.2%, while Latin America, EMEA and Asia Pacific grew 5.4%, 3.5% and 5.6%, respectively. (investor.colgatepalmolive.com)
Management maintained its annual sales and EPS forecasts but changed full-year gross-margin guidance from up to down. The revision reflected approximately $300 million of incremental raw-material and logistics costs, based partly on an assumption of roughly $110 oil for the balance of the year.
That cost reset makes Q2’s guidance discussion at least as important as the quarter’s reported EPS.
Q1’s best feature was the return to positive volume, led by Asia and other emerging markets. Excluding lower private-label pet-food sales, management said Colgate generated both volume and pricing growth across all four product categories.
The Q2 bar is not particularly high: organic sales grew only 1.8% in Q2 2025, with organic volume down 0.2%. But category growth has remained sluggish, and management observed additional U.S. category slowing beginning in May.
A healthy composition would look like:
A weaker result would be organic growth below 2%, especially if positive pricing masks renewed volume contraction.
North America was only 17% of Q1 sales but represented the company’s largest execution problem:
The margin pressure reflected weak sales leverage, higher raw-material costs and tariffs. Management attributed some of the volume weakness to delayed shelf resets and late innovation shipments and said performance should improve sequentially beginning in Q2.
A June investor conference provided a more mixed update. Colgate said U.S. categories slowed markedly in early May, although Oral Care share appeared to stabilize. The recovery plan centers on:
An immediate return to growth is probably unrealistic. The more reasonable test is whether:
Organic sales around flat would be encouraging. Another decline of 2% or worse—particularly if paired with lower share—would call the timing of the turnaround into question.
This is likely the report’s most important financial issue.
In May, management estimated that incremental 2026 cost pressure had increased by about $300 million:
Management planned to offset the pressure through productivity, revenue growth management, premium innovation, mix and selective pricing. It explicitly said broad headline pricing would be approached cautiously in the United States given consumer pressure.
A Q2 gross margin near or above the 60% area, combined with unchanged annual guidance, would probably be viewed as adequate. The bigger risk is another negative gross-margin revision that forces investors to question the durability of EPS growth in 2027.
Emerging markets generated 6.2% organic growth in Q1, supported by positive volume and pricing. Their continued strength is crucial because developed-market organic growth was nearly flat.
Latin America contributed 25% of Q1 sales and delivered:
Management remains confident in Mexico and Brazil and has highlighted premium Oral Care innovation, including Optic and Purple, along with Home Care brands such as Suavitel.
The watch item is whether growth remains balanced. A result driven solely by pricing would be less reassuring than continued positive volume.
Asia Pacific’s 5.6% Q1 organic growth was one of the quarter’s most encouraging developments. Volume increased 4.6%, aided by India and better performance in China.
Investors should look for:
Sustained mid-single-digit Asia growth would help establish that Q1 was more than a one-quarter rebound.
Hill’s reported only 2.1% Q1 organic growth, but that included a substantial drag from the planned private-label pet-food exit. Excluding private label, management said Hill’s organic sales grew approximately 4.8%, including positive core volume.
The company previously indicated that the private-label exit would reduce total-company Q2 growth by approximately 20–30 basis points and should be largely out of the comparison by the second half.
The underlying Hill’s business remains attractive:
Investors should evaluate Hill’s excluding the private-label noise. Core growth in the mid-single digits, accompanied by stable or improving margins, would be a solid result.
The risks are continued weakness in large-format dry dog food, consumer trade-down and signs that the premium pet-food category is deteriorating more broadly.
Colgate expanded its Strategic Growth and Productivity Program in Q1:
The program supports the long-term margin and investment story, but investors should not count on it to fully solve the immediate Q2 cost problem.
For Friday, the relevant issues are:
Management has been clear that cuts to advertising, data and AI investment are not its preferred response to inflation. Maintaining that stance while preserving EPS guidance would support confidence in the business model.
Current 2026 guidance calls for:
Based on 2025 adjusted EPS of $3.69, the EPS framework implies approximately $3.80–$3.87 for 2026. At $91.62, CL trades at roughly 24 times that range.
That valuation does not require rapid growth, but it does require dependable execution. Maintaining guidance with a credible path to margin stabilization would likely be sufficient. A lower EPS forecast would be more damaging than a modest Q2 revenue miss.
| Scenario | What it might look like | Likely interpretation |
|---|---|---|
| Bull case | Organic growth above 3.5%; positive volume; North America approaches flat; Hill’s core growth near 5%; gross margin better than feared; guidance maintained with a constructive second-half outlook | Q1 momentum is durable and cost mitigation is working |
| Base case | Organic growth of 2%–3%; North America remains negative but improves; emerging markets stay healthy; gross margin declines; full-year guidance is reiterated | Adequate execution, but limited reason for meaningful multiple expansion |
| Bear case | Organic growth below 2%; company-wide volume turns negative; North America fails to improve; Asia slows; cost assumptions rise again; gross-margin or EPS guidance is reduced | Growth and margin pressures are becoming structural rather than temporary |
CL closed July 30 at $91.62:
The stock’s outperformance and approximately 24x earnings multiple create an asymmetrical setup: the company does not need a spectacular quarter, but investors are unlikely to overlook another material deterioration in the cost or North American outlook.
The strongest part of the CL thesis remains its global diversification: Latin America is highly profitable, Asia has begun to recover, and Hill’s continues to outgrow its category. The weakest part remains North America, where the company is attempting a multiyear reset just as the consumer and category environment soften.
For this quarter, gross-margin credibility matters more than the precise EPS beat or miss. The best outcome would combine positive organic volume, measurable North American improvement and unchanged annual guidance despite the oil and logistics shock.
A modest headline beat without progress on those issues would be low quality. Conversely, even an in-line quarter could be received well if management demonstrates that the May cost reset was conservative and that the full-year EPS algorithm remains intact.